Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Loss of ARID1A expression in endometrial samplings is associated with the risk of endometrial carcinoma.

Gynecologic oncology - 1 Sept 2018

Yen Ting-Tai, Miyamoto Tsutomu, Asaka Shiho, Chui M Herman, Wang Yeh, Lin Shiou-Fu, Stone Rebecca L, Fader Amanda N, Asaka Ryoichi, Kashima Hiroyasu, Shiozawa Tanri, Wang Tian-Li, Shih Ie-Ming, Tanner Edward J

Abstract excerpt

OBJECTIVES: Inactivating somatic mutations of ARID1A, a chromatin remodeling gene, are common in endometrioid endometrial carcinoma (EEC) but rare in complex atypical hyperplasia (CAH). Our objectives were to determine the clinical significance of ARID1A loss during tumor progression from CAH to EEC and to assess its role as a predictive cancer biomarker. METHODS: In cohort A, ARID1A immunoreactivity was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma
Share to Disease Progression

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Endometrial Hyperplasia

Share to Endometrial Neoplasms

Share to Hysterectomy

Share to Neoplasm Grading

Share to Neoplasm Staging

Share to Predictive Value of Tests

Source

Identifiers

PMID: 30126589
DOI: 10.1016/j.ygyno.2018.06.025

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Loss of ARID1A expression in endometrial samplings is associated with the risk of endometrial carcinoma.PMID 30126589Read ↗

ARID1A is a useful marker of malignancy in peritoneal washings for endometrial carcinoma.Semantic proximity Read ↗

ARID1A: gene, protein, and function in endometrial cancer.Semantic proximity Read ↗

ARID1A deficiency associated with MMR deficiency and a high abundance of tumor-infiltrating lymphocytes predicts a good prognosis of endometrial carcinomaSemantic proximity Read ↗

ARID1A in Gynecologic Precancers and Cancers.Semantic proximity Read ↗

Clonal evolution in paired endometrial intraepithelial neoplasia/atypical hyperplasia and endometrioid adenocarcinoma.Semantic proximity Read ↗

Endocervical-type mucinous borderline tumors are related to endometrioid tumors based on mutation and loss of expression of ARID1A.Semantic proximity Read ↗

Characterizing the Discordance between AT-Rich Interacting Domain 1A Protein and Genotype in Endometrioid-Type Endometrial Tumors.Semantic proximity Read ↗

Landscape of chromatin remodeling gene alterations in endometrial carcinoma.Semantic proximity Read ↗

Down-regulation of ARID1A is sufficient to initiate neoplastic transformation along with epigenetic reprogramming in non-tumorigenic endometriotic cells.Semantic proximity Read ↗

The roles of ARID1A in gynecologic cancerSemantic proximity Read ↗

The emerging roles of ARID1A in tumor suppression.Semantic proximity Read ↗

Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.